"approved"@en . "A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)"@en . . " "@en . "# Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15530999 # Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15276195 # Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8322081"@en . . "78-44-4"@en . "Isopropyl meprobamate"@en . "For the relief of discomfort associated with acute, painful, musculoskeletal conditions."@en . . . "N-Isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate"@en . . . . "2-Methyl-2-propyltrimethylene carbamate isopropylcarbamate"@en . . . "Carisoprodol"@en . . . . . . . . "60%"@en . "Someprobamate"@en . . . "Carisoprodol is eliminated by both renal and non-renal routes."@en . . . . . . "Isomeprobamate"@en . "2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate"@en . . . . . . . . . . "Isopropylmeprobamate"@en . . . . . . . . . . . "(1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester"@en . . . . . . . . . . . . . . . "Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester"@en . . . . . . . . "Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc."@en . . . . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . "* oral cl=0.772 L/hour/kg [Women] * oral cl=0.38 L/hour/kg [Men]"@en . . . . . . . . . . . . . . . "Carisoprodate"@en . . . . . . . . . . . . . . "(+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate"@en . . . . . . . . "8 hours"@en . . . . . . . . "Avoid alcohol."@en . . . . . "Isobamate"@en . . . . . "Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives"@en . "Take without regard to meals."@en . "Carisoprodol"@en . . . . . . . . . . . . "Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known."@en . . . "Carisoprodolum"@en . . . . "(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate"@en . . .